Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs.

Current clinical and preclinical anticancer formulations are limited by their use of toxic excipients and stability issues upon combining different drug formulations. We have found that poly(ethylene glycol)-block-poly(d,l lactic acid) (PEG-b-PLA) micelles can deliver multiple poorly water-soluble drugs at clinically relevant doses. Paclitaxel (PTX), etoposide (ETO), docetaxel (DCTX) and 17-allylamino-17-demethyoxygeldanamycin (17-AAG) were solubilized individually in PEG-b-PLA micelles. Combinations of PTX/17-AAG, ETO/17-AAG, DCTX/17-AAG and PTX/ETO/17-AAG were also solubilized in PEG-b-PLA micelles. PEG-b-PLA micelles were characterized in terms of drug loading, size, stability and drug release. All anticancer agents in all combinations were all solubilized at the level of mg/mL and were stable for 24 h in the 2- and 3-drug combination PEG-b-PLA micelles. The stability of the 2- and 3-drug combination PEG-b-PLA micelles was due to the presence of 17-AAG. In vitro, t(1/2) values for 2- and 3-drug combination PEG-b-PLA micelles spanned 1-5 h. PEG-b-PLA micelles offer a promising alternative for combination drug therapy without formulation related side effects.

[1]  Yokoyama Masayuki,et al.  Block copolymer micelles as vehicles for drug delivery , 1993 .

[2]  Sung-Bae Kim,et al.  Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer , 2008, Breast Cancer Research and Treatment.

[3]  V. Torchilin,et al.  Structure and design of polymeric surfactant-based drug delivery systems. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[4]  S. Kawakami,et al.  Block copolymer design for stable encapsulation of N-(4-hydroxyphenyl)retinamide into polymeric micelles in mice. , 2008, International journal of pharmaceutics.

[5]  C. Hudis,et al.  Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Wolchok,et al.  Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma , 2008, Clinical Cancer Research.

[7]  G. Kwon,et al.  Clinical developments in drug delivery nanotechnology. , 2008, Advanced drug delivery reviews.

[8]  A. Narendran,et al.  Effects of 17-Allylamino-17-Demethoxygeldanamycin (17-AAG) on Pediatric Acute Lymphoblastic Leukemia (ALL) with Respect to Bcr-Abl Status and Imatinib Mesylate Sensitivity , 2005, Pediatric Research.

[9]  S. Ramalingam,et al.  A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies , 2008, Clinical Cancer Research.

[10]  S. Pennington,et al.  The topoisomerase II–Hsp90 complex: A new chemotherapeutic target? , 2006, International journal of cancer.

[11]  G. Kwon,et al.  Poly(ethylene glycol)-b-poly(epsilon-caprolactone) and PEG-phospholipid form stable mixed micelles in aqueous media. , 2006, Langmuir : the ACS journal of surfaces and colloids.

[12]  H. S. Oh,et al.  In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[13]  P. Low,et al.  Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo forster resonance energy transfer imaging. , 2008, Langmuir : the ACS journal of surfaces and colloids.

[14]  J. Verweij,et al.  Pharmacological Effects of Formulation Vehicles , 2003, Clinical pharmacokinetics.

[15]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[16]  B. Weinberg,et al.  Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[17]  D. Schrump,et al.  Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. , 2001, The Annals of thoracic surgery.

[18]  W. Lorenz,et al.  Histamine release in dogs by Cremophor El® and its derivatives: Oxethylated oleic acid is the most effective constituent , 1977, Agents and Actions.

[19]  D. Brocks,et al.  Disposition of Drugs in Block Copolymer Micelle Delivery Systems , 2008, Clinical Pharmacokinetics.

[20]  B. Leyland-Jones,et al.  Hypersensitivity reactions from taxol. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Kersey,et al.  Synergism between Etoposide and 17-AAG in Leukemia Cells: Critical Roles for Hsp90, FLT3, Topoisomerase II, Chk1, and Rad51 , 2007, Clinical Cancer Research.

[22]  Simon Thomas,et al.  Simulation modelling of human intestinal absorption using Caco-2 permeability and kinetic solubility data for early drug discovery. , 2008, Journal of pharmaceutical sciences.

[23]  Y. Matsumura.  Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. , 2008, Advanced drug delivery reviews.

[24]  B. Krishnan,et al.  Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT , 2006, Molecular Cancer Therapeutics.

[25]  K. Hande,et al.  Etoposide: four decades of development of a topoisomerase II inhibitor. , 1998, European journal of cancer.

[26]  R. Govindan,et al.  Novel formulations of taxanes: a review. Old wine in a new bottle? , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  N. Davies,et al.  A cremophor-free formulation for tanespimycin (17-AAG) using PEO-b-PDLLA micelles: characterization and pharmacokinetics in rats. , 2009, Journal of pharmaceutical sciences.

[28]  G. Kwon,et al.  In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[29]  J. Watkins,et al.  Suspected anaphylactic reaction to Cremophor EL. , 1980, British medical journal.

[30]  D. Solit,et al.  Development and application of Hsp90 inhibitors. , 2008, Drug discovery today.

[31]  A. Olshen,et al.  Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. , 2003, Cancer research.

[32]  A. Lavasanifar,et al.  Micelles of methoxy poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization and controlled delivery of cyclosporine A. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[33]  D. Schrump,et al.  Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin. , 1999, The Journal of thoracic and cardiovascular surgery.

[34]  Kinam Park,et al.  Hydrotropic polymeric micelles for enhanced paclitaxel solubility: in vitro and in vivo characterization. , 2007, Biomacromolecules.

[35]  D. Ruden,et al.  Possible effects of early treatments of hsp90 inhibitors on preventing the evolution of drug resistance to other anti-cancer drugs. , 2007, Current medicinal chemistry.

[36]  J. Aubé,et al.  Butitaxel analogues: synthesis and structure-activity relationships. , 1997, Journal of medicinal chemistry.

[37]  J. R. Sneyd,et al.  Anaesthetic effects of propofol polymeric micelle: a novel water soluble propofol formulation. , 2008, British journal of anaesthesia.

[38]  L. Norton,et al.  Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155- , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  P. Gellert,et al.  Poly(lactic acid)−Poly(ethylene oxide) (PLA−PEG) Nanoparticles: NMR Studies of the Central Solidlike PLA Core and the Liquid PEG Corona , 2002 .

[40]  Yaoquan Liu,et al.  Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. , 2004, Bioorganic & medicinal chemistry.